Sinotherapeutics (SH:688247) Xin Lang Cai Jing·2025-09-02 02:04Group 1 - The core viewpoint of the news is that Xuantai Pharmaceutical has shown significant trading activity and financial performance, with a notable increase in financing and a slight decrease in net profit year-on-year [1][2]. - On September 1, Xuantai Pharmaceutical's stock rose by 1.74%, with a trading volume of 64.42 million yuan. The financing buy-in amount for the day was 9.68 million yuan, while the net financing purchase was 6.27 million yuan [1]. - As of September 1, the total balance of margin trading for Xuantai Pharmaceutical was 88.76 million yuan, accounting for 1.67% of its market capitalization, indicating a high level of financing activity compared to the past year [1]. Group 2 - As of June 30, the number of shareholders for Xuantai Pharmaceutical was 8,020, a decrease of 4.40% from the previous period, while the average circulating shares per person increased by 4.60% to 17,745 shares [2]. - For the first half of 2025, Xuantai Pharmaceutical reported a revenue of 220 million yuan, a year-on-year increase of 0.74%, but the net profit attributable to shareholders decreased by 15.82% to 45.59 million yuan [2]. - Since its A-share listing, Xuantai Pharmaceutical has distributed a total of 74.36 million yuan in dividends [3].